Security woes halt Army research

The army's top infectious disease institute suspended its biodefense research on Friday (February 6) after finding problems with its system for keeping track of the dangerous pathogen stocks found in its labs. The blog linkurl:ScienceInsider;http://blogs.sciencemag.org/scienceinsider/2009/02/us-army-lab-fre-1.html obtained an internal memo from the institute, the U.S. Army Medical Research Institute of Infectious Diseases (USAMRID), informing employees it had begun an extensive inventory that

Written byAlla Katsnelson
| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share
The army's top infectious disease institute suspended its biodefense research on Friday (February 6) after finding problems with its system for keeping track of the dangerous pathogen stocks found in its labs. The blog linkurl:ScienceInsider;http://blogs.sciencemag.org/scienceinsider/2009/02/us-army-lab-fre-1.html obtained an internal memo from the institute, the U.S. Army Medical Research Institute of Infectious Diseases (USAMRID), informing employees it had begun an extensive inventory that will make sure all substances available in labs are noted in a database. "I believe that the probability that there are additional vials of BSAT [biological select agents and toxins] not captured in our database is high," wrote institute commander Col. John Skvorak in the memo. USAMRID is the facility at which Bruce Ivins studied anthrax. The US government alleges Ivins coordinated the anthrax mailings of 2001. He committed suicide last summer, after which the Army began a review of its protocols for working with bioterror pathogens.
**__Related stories:__***linkurl: How to fix biosecurity?;http://www.the-scientist.com/blog/display/55166/
[ 4th November 2008]*linkurl: Kansas wins controversial biolab?;http://www.the-scientist.com/blog/display/55260/
[ 4th December 2008]*linkurl:Biosafety lapse prompts govt review;http://www.the-scientist.com/news/display/53626/
[ 25th September 2007]
Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Meet the Author

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies